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Dietary selenium has potent cancer prevention activity. Both low
molecular weight selenocompounds and selenoproteins are implicated in
this effect. Thioredoxin reductase 1 (TR1) is one of the major antioxidant
and redox regulators in mammals that supports p53 function and other
tumor suppressor activities. However, this selenium-containing oxi-
doreductase is also overexpressed in many malignant cells and has been
proposed as a target for cancer therapy.To further assess the role ofTR1 in
themalignancy process, we usedRNA interference technology to decrease
its expression inmouse lung carcinoma (LLC1) cells. Stable transfectionof
LLC1 cells with a small interfering RNA construct that specifically targets
TR1 removal manifested a reversal in the morphology and anchorage-
independent growth properties of these cancer cells that made them sim-
ilar to those of normal cells. The expression of at least two cancer-related
protein mRNAs, Hgf and Opn1, were reduced dramatically in the TR1
knockdown cells. Mice injected with the TR1 knockdown showed a dra-
matic reduction in tumor progression and metastasis compared with
those mice injected with the corresponding control vector. In addition,
tumors that arose from injected TR1 knockdown cells lost the targeting
construct, suggesting that TR1 is essential for tumor growth in mice.
These observations provide direct evidence that the reduction of TR1 lev-
els in malignant cells is antitumorigenic and suggest that the enzyme is a
prime target for cancer therapy.
There are 25 selenoproteins in humans and 24 in rodents (1), and of those
with known functions, most serve as antioxidants (reviewed in Refs. 2 and 3).
One of these selenoproteins, thioredoxin reductase 1 (TR1),2 is one of the
major antioxidant and redox regulators inmammalian cells. TR1 is an essential
protein (4) that is expressed in all cell types and organs (2, 3), and the Sec
moiety is essential for its activity (5, 6). Interestingly, it is overexpressed in
many malignant cells (e.g. see Refs. 7–10). A variety of potent TR1 inhibitors
have been shown to alter the cancer-related properties of tumors and numer-
ous malignant cells (see Refs. 7–13 and references therein). For example,
recently, a potent antitumor drug, 1,2-[bis (2-benzysoselenazolone-3(2H)-ke-
tone)]ethane, was found to reverse the phenotype of five human carcinoma cell
lines (13). Furthermore, reduction of TR1 activity in human hepatocellular
carcinoma cells by transfection with TR1 antisense RNA inhibited cell growth
(14). TR1 has therefore been implicated as a potential target for cancer therapy
(e.g. see Refs. 7, 9, 10, and 15).
On the other hand, TR1 is a selenoprotein that activates tumor suppressor
p53 (16) and is specifically targeted by carcinogenic electrophiles (17, 18).
Dietary seleniumalso has potent cancer prevention activity (see Refs. 19 and 20
and references therein). These latter studies have implicated TR1 in tumor
suppression, and thus, the overall role of TR1 in tumor progression remains
unclear. To further assess the role of TR1 in tumor progression, we used RNA
interference technology to knock down its expression in a mouse lung cancer
cell line, mouse Lewis lung carcinoma (LLC1) cells, and have observed a rever-
sal of the tumor phenotype. In addition, the tumorgenicity and metastatic
properties of the TR1 knockdown cells were dramatically reduced further sug-
gesting that TR1 is indeed a target for cancer therapy in malignant cell lines
that overexpress this selenoprotein.
EXPERIMENTAL PROCEDURES
Materials—All materials were commercial products of the highest grade
available and are described in the supplemental data or elsewhere (21, 22).
Mouse Lewis lung carcinoma cells, designated LLC1, were obtained from the
American Type Culture Collection (ATCC).
Knockdown of TR1—The pU6-m3 vector used for generating siRNA targets
was constructed using the pSilencer 2.1-U6 Hygro vector as the backbone
(details of this vector and its use as a knockdown construct are given in Ref. 22).
Changes were inserted into the vector as follows: 1) GC bases at positions 468
and 469 were changed to an A making the U6 promoter more homologous to
the corresponding wild type gene; 2) the EcoRI site was deleted at position
4110; and 3) a XhoI site was added at position 384. Changing these two cloning
sitesmade it possible to insertmultiple siRNA target sequences into the vector.
The 3-untranslated region of mouse TR1 mRNA (accession number:
NM_015762) was surveyed using diDESIGN program (Dharmacon, Inc.) to
select potential targeting sites for its knockdown. Sense-antisense oligonucleo-
tides for TR1 knockdown and its control, which had mutations in the target
sequences (i.e. the targeting construct encoded gtctcactttcaagctgtctaa and the
corresponding siTR1 control encoded atcgctctgacaagcttattag, where the
underlined bases show mutations in the wild type targeting sequence), were
annealed and inserted into the BamHI-HindIII cloning sites in pU6-m3
according to instructions detailed in the cloningmanual of the pSilencer 2.1U6
Hygro vector. The sequences of the resulting constructs, designated siTR1 or
pU6 control, were confirmed by sequencing.
Culture of Mammalian Cells and Transfection Studies—LLC1 cells were
grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum and antibiotic-antimycotic solution at 37 °C as described in the
product description packet from ATCC. Cells were maintained by splitting
every 3 days using trypsin-EDTA. Stably transfected siTR1 (knockdown) cells
and stably transfected pU6 control cells were prepared by transfectingwith the
corresponding constructs using Lipofectamine 2000 and then selecting cells in
the presence of 500 g/ml of hygromycin B.
Northern Blot Analysis—Techniques for isolating RNA and carrying out
Western blots have been detailed elsewhere (21, 22) and/or are given in the
supplemental data. The full-length probe for TR1 mRNA was as described
(22).
Western Blot Analysis—Techniques used for Western blot analysis have
been described elsewhere (21, 22) and/or are given in the supplemental data.
75Se Labeling of Cells—Cells were seeded onto a 6 well plate (3105 cells/
well), incubated for 24 h, then labeled with 40 Ci of 75Se (20 nM) for 24 h,
harvested, and lysed as described above. 40 g of each sample were applied to
NuPAGE 10% BisTris gel, electrophoresed, proteins stained with Coomassie
Blue staining solution, the gel dried, and exposed to a PhosphorImager (Amer-
sham Biosciences) (see supplemental data). 75Se-Labeled selenoproteins on
exposed gels have been identified previously (see Refs. 21 and 22 and references
therein).
Assay of TR Activity—TR enzyme activity was measured in control LLC1
cell lysates or LLC1 cell lysates from cells stably transfected with either pU6
control or siTR1 constructs as described (23).
Soft AgarAssay—Atotal of 1000 control orTR1 knockdown cells suspended
in 3ml of 0.35% noble agar (growthmediumwith 10% fetal bovine serum)were
spread evenly onto 60-mm plates masked with a 4-ml basal layer of 0.7% noble
agar in Dulbecco’s modified Eagle’s medium. The plates were then incubated
in a humidified 37 °C incubator for 14 days, adding growth medium onto the
* This research was supported by the Intramural Reseach Program of the National Insti-
tutes of Health, NCI, Center for Cancer Research and by Grants GM065204 and
CA080946 (to V. N. G.). The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby marked “adver-
tisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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mental data, Figs. 1 and 2, and Ref. S1.
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agar plate every 5 days. The colonies that developedwere visualized by staining
with -iodonitrotetrazolium violet overnight and counted.
Tumor Formation Assay—To check tumor formation capability, 2105 of
siRNA control cells (pU6 control) or TR1 knockdown cells (siTR1) that have
been maintained in the growth phase were subcutaneously injected into the
flanks of mice (female 5-week-old C57BL/6) and tumor formation monitored
every 2 days. At 2 weeks following injection, the mice were euthanized and the
tumors removed and analyzed. To assess the metastatic capability of these cell
lines, 2  105 cells of each were injected into the tail veins of mice. After 4
weeks of intravenous injection, mice were euthanized and the lung tissues
dissected and analyzed. Animal care was in accordance with the National
Institutes of Health institutional guidelines under the expert direction of Dr.
Kyle Stump (NCI, National Institutes of Health, Bethesda, MD).
RESULTS
Knockdown of TR1 mRNA and TR1—The siTR1 construct and the corre-
sponding pU6 control construct were prepared as described under “Experi-
mental Procedures” and used to transfect LLC1 cells. LLC1 cells were either
stably transfected with the pU6 control construct or the siTR1 construct, or
untransfected, and the levels of TR1, TR1 mRNA, and TR activity determined
(Fig. 1). Each cell linewas initially labeledwith 75Se to examine the levels of TR1
and other selenoproteins and the ability of the siTR1 construct to knockdown
TR1 expression. The relative intensities of the various 75Se-labeled bands were
determined using a PhosphorImager that demonstrated that TR1 levels were
most severely affected (see Fig. 1A and supplemental Fig. 1). Northern blot
analysis (Fig. 1B),Western blot analysis (Fig. 1C), and direct assay (Fig. 1D) also
demonstrated that the expression of TR1 mRNA, TR1, and TR1 activity,
respectively, was efficiently knocked down by the siRNA vector.
Phenotypic Changes in TR1 Knockdown Cells—Since the pU6 control con-
struct did not appear to have any effect on TR1 expression in LLC1 cells (see
Fig. 1), further studies were carried out only with the LLC1 cells transfected
with pU6 and siTR1 constructs. As expected, cells transfected with the pU6
control construct grew in multilayer and loosely attached to the culture dish
(Fig. 2A), which are characteristics of malignant cells. However, cells trans-
fected with the siTR1 construct grew in monolayer and tightly attached to the
culture dish, which are growth properties characteristic of normal cells. The
growth rate of the siTR1-transfected cells was slightly retarded compared with
pU6-transfected cells; that is, it was reduced by25% at 72 h (Fig. 2B). While
the inhibition of growth rates in the TR1 knockdown was noticeable, this
phenotype was mild, considering that this enzyme is essential during embry-
onic development (4).
Another characteristic of many cancer cells is that they can grow unan-
chored in soft agar, while many normal cells do not grow under such condi-
tions. The colonies present after 2weeks growth in soft agar of the two cell lines
transfectedwith either the pU6 control or siTR1 construct were photographed
and the data quantitated as shown in Fig. 2, C and D, respectively. Clearly,
growth of the TR1 knockdown cells in soft agar was inhibited as evidenced by
colony numbers and colony size compared with the pU6-transfected cells.
Changes in Cancer-related Components in TR1 Knockdown Cells—RNA
extracts from LLC1 cells transfected with either the pU6 control or siTR1
construct were examined for differences in the expression of 96 cancer-related
marker mRNAs (see supplemental Fig. 2). Two of the boxes, designated H for
hepatocyte growth factor (Hgf) mRNA and O for osteopontin (Opn1) mRNA,
were reduced in RNA extracts from siTR1-transfected compared with pU6-
transfected cells. Boxes corresponding to several other factors and to controls
are also identified in the supplemental data. Both Hgf (24) and Opn1 (25) play
important roles in metastasis and tumor growth. The mRNA levels of both
cancer promoting factors were quantitated as described under “Experimental
Procedures” and found to be reduced more than 2.5-fold in siTR1-transfected
cells as compared with pU6-transfected cells (data not shown). The mRNA
levels of both components were further examined by Northern blot analysis
and also found to be substantially reduced in siTR1-transfected cells as com-
pared with control cells (Fig. 2E).
Tumorigenesis and Metastasis of siTR1 Knockdown Cells—To assess the
tumorigenicity and metastasis of the pU6- and siTR1-transfected cells, mice
were injected in the flank with either of the cell lines. Tumor progression was
analyzed after 2 weeks by euthanizing the animals and examining the tumors.
Tumors were much larger in mice injected with the pU6 control-transfected
cells with an averageweight of 0.341 g comparedwith an average tumorweight
of 0.063 g in mice injected with the siTR1-transfected cells (see Fig. 3A and
legend). This dramatic difference in tumor growth in mice contrasted with
slight changes in growth rates due to TR1 knockdown in cell culture (compare
FIGURE 1. Knockdown of TR1 in LLC1 cells. LLC1
cells were either untransfected (designated LLC1)
or stably transfected with the pU6 control or siTR1
construct (as indicated) and the expression of TR1
examined by labeling cells with 75Se (A), Northern
blotting (B), Western blotting (C), or TR enzyme
assay (D). Lanes represent cell extracts of 1)
untransfected LLC1 cells, 2) cells transfected with
pU6 control, and 3) cells transfectedwith the siTR1
construct in A–C. Selenoproteins identified in pre-
vious studies are indicated on the right side and
molecular weightmarkers on the left side of A; and
18 and 28 S ribosomal units are indicated on the
right side of the lower portion of C.
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FIGURE 2. Phenotypic changes in TR1 knockdown cells and analysis of gene products associated with malignancy. LLC1 cells were transfected with the pU6 control or siTR1
construct and theirmorphologyexaminedduringexponential growth (A) or their growth rates quantitated (B). Cellswerephotographedwith an invertedphase contrastmicroscope.
Cells were seeded at a density of 2  105 cells/60-mm culture dish and growth rates determined by counting cell numbers at 24, 48, and 72 h. C, colonies were stained with
-iodonitrotetrazolium violet overnight at 37 °C and the stained colonies counted and recorded as the total number of colonies (D) (solid dark rectangles), colonies greater than 0.7
mm in size (gray rectangles), and colonies 0.7 mm or less in size (white rectangles). E, Northern blots of RNA extracts from pU6 control (lane 1)- and siTR1 (lane 2)-transfected cells.
Relative intensities of 18 and 28 S ribosomal subunits are shown in lower panel of E.
FIGURE 3. Tumorigenicity and metastasis of
LLC1-transfected cells.Mice were injected in the
flank with cells expressing pU6 or TR1 knockdown
constructs. A, tumor formation was monitored
every 2 days; after 2 weeks, micewere euthanized,
tumors removed from the flanks, weighed
(weights were averaged from three separate
mice), and photographed. A, TR1 Western blot
analysis in tumor extracts; and A, PCR analysis of
genomicDNA fromtumormasses for thepresence
of the pU6 and TR1 siRNA construct. B, metastasis
was assessed after 4 weeks whereby mice were
euthanized and the lungs removed and photo-
graphed; and B, lung tissue slices examined for
pathological changes. Arrows indicate tumor
regions resulting from injected pU6 control cells.
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Figs. 3A and 2B). In addition, since the constructs were retained in stably
transfected cells with the counter-selecting antibiotic, hygromycin B, and the
injected mice could not be treated with this drug, it was possible that tumor
growth in mice injected with the siTR1-transfected cells might be due to the
loss of the siTR1 targeting vector. Indeed, Western blot analysis showed that
tumors developed from both siTR1- and pU6-transfected cells expressed high
levels of TR1, further suggesting that low levels of TR1 did not support tumor
growth and that tumors reappeared due to reversal of the TR1 knockdown
(Fig. 3A). Consistent with this observation, PCR analysis of genomic DNA
from both siTR1 and pU6 tumors showed that the TR1 siRNA construct was
lost from tumor cells that were injected with the knockdown vector (Fig. 3A).
Tumor metastasis was analyzed after 4 weeks by euthanizing the mice and
examining the lungs. Tumors were readily apparent in the lungs of mice
injected in a tail vein with the pU6 vector-expressing cells, while no tumors
were visible inmice injectedwith cells containing the siTR1 construct (Fig. 3B).
Histological analysis of lung tissue showed extensive malignancy in mice
injected with the pU6 construct, but only normal tissue was found in mice
injected with the siTR1 construct (Fig. 3B).
DISCUSSION
Redox-sensitive signaling factors governmultiple cellular processes, such as
proliferation, cell cycle events, and numerous signaling cascades relating to
proper cell function (reviewed in Refs. 26 and 27). TR1 is an essential protein
(4) and a central component in several redox-regulated pathways. Its main
function is to keep thioredoxin in the reduced state (28). In turn, thioredoxin
donates electrons to disulfides in cytosolic and nuclear proteins, thus main-
taining cysteine residues in these proteins in the reduced state.
Among other pathways dependent on thioredoxin, TR1 is critical for the
proper function of tumor suppressor p53, and inhibition of TR1 by carcinoge-
netic, electrophilic compounds implicated this protein in cancer prevention
(17). In addition, TR1 contains an essential selenocysteine residue. Selenium is
known as a trace element with potent cancer prevention function (19, 20). On
the other hand, since overexpression of TR1 is consistently observed in many
tumors and several antitumor drugs are known inhibitors of TR1 (29–31), this
selenoenzyme was proposed as a target for tumor therapy (7, 9, 10, 15, 32). In
addition, selenium deficiency has been reported to decrease tumor incidence
in some cancer models in animals (33). Thus, the contrasting functions of TR1
in regard to tumor development and growth complicate the assessment of its
role in cancer.
In this study, we inhibited TR1 expression using RNA interference technol-
ogy without affecting the expression of other major selenoproteins. TR1 defi-
ciency was not lethal in cell culture and in fact only slightly reduced growth
characteristics of the knockdown cells compared with the cells transfected
with the control vector. In contrast, we observed dramatic changes in tumor
growth andmetastasis, when these cells were injected intomice. Further stud-
ies on the knockdown cells revealed that the TR1 deficiency reversed the phe-
notype ofmalignant cells rather than simply reducing cell growth. Importantly,
the tumors observed inmice injected with the knockdown cells lost the target-
ing construct, suggesting that TR1 is essential for tumor growth but not for
growth of cells in culture. It is clear that some cell types, e.g. T cells,3 and even
organs, e.g. liver (34), can function without TR1, or for that matter, all seleno-
proteins, as the targeted removal of the Sec tRNA[Ser]Sec gene in this cell type
or organ, is not lethal. Thus, TR1 expression is not essential to all cell types as
seems to also be true of LLC1 cells. Overall, our data show that down-regulat-
ing TR1 expression alters the redox homeostasis and in turn reverts the phe-
notype of malignant cells more in line with that of normal cells. Thus, TR1
provides an excellent molecular target for cancer therapeutic intervention.
How can this apparently essential function of TR1 in cancer development be
reconciled with the role of TR1 in tumor suppression and the known anti-
cancer role of selenium? We speculate that TR1 and selenium act as cancer
prevention factors by regulating cellular redox homeostasis (a balance between
reductive and oxidative processes in the cell) and protecting against mutations
and oxidative damage to DNA and proteins. However, in newly emerged
tumors, TR1 is required to sustain tumor growth, probably because of the
increased dependence on the reducing equivalents provided by thioredoxin for
various biosynthetic processes. Apparently, this TR1 dichotomy requires the
thioredoxin pathway, due to the many targets of this protein. This hypothesis
could explain both the potent cancer prevention activity of dietary selenium
(19, 20) and the potent antitumor activity of drugs that target TR1 (7–13).
Most importantly, this study provides a foundation to explain literature data
on the role of TR1 in cancer and establishes this enzyme as a prime target for
cancer therapy.
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SUPPLEMENTARY INFORMATION 
Supplementary Materials and Methods 
     Materials - 75Se (specific activity 1000 Ci/mmol) was obtained from the Research Reactor Facility, 
University of Missouri, Columbia, MO, [α-32P]CTP (specific activity 6000 Ci/mmol) from Perkin Elmer 
and Hybond-N+ nylon membrane, Ready-To-Go DNA labeled Bead and probeQuant G-50 MicroColumns 
from Amersham Biosciences and PVDF membranes, NuPage 10% Bis-Tris gels, Trizol reagent, 
hygromycin B and lipofectamine 2000 from Invitrogen Life Technologies. siRNA vector pSilencer 2.1-
U6 Hygro was purchased from Ambion, Inc., Mouse Cancer Pathway Finder Gene Array from 
SuperArray Bioscience Company, BCA protein assay reagent from Pierce ρ-iodonitrotetrazolium violet 
(INT) from Sigma and Dulbecco’s modified Eagle’s medium (DMEM), antibiotic-antimycotic solution 
and 10% fetal bovine serum from Life Technologies, Inc. 
     Northern blot analysis - Total RNA was isolated from cultured cells with Trizol reagent according to 
the manufacturer’s protocol. 12 µg of total RNA were electrophoresed on a 1.2% formaldehyde-agarose 
gel, transferred to a Hybond-N+ nylon membrane and cross-linked using a UV-Stratalinker. Probes were 
prepared by random labeling with [α-32P]CTP using the Ready-To-Go DNA Labeled Bead kit and non-
incorporated nucleotides removed using probe Quant G-50 MicroColumn following the manufacturer’s 
procedure. Membranes were hybridized with labeled probes, washed and exposed to a PhosphorImager 
(Molecular Dynamics). TR1 mRNA expression ratios were obtained using ImageQuant program 
(Molecular Dynamics). 
     Western blot analysis - Cells were washed in cold PBS and whole cell lysates prepared using lysis 
buffer (20 mM Tris-Cl, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 10 mM NaF, 5 mM 
EGTA, 0.5 mM PMSF and proteinase inhibitor cocktail) as described (S1). Protein concentrations were 
measured using BCA protein assay reagent and 30 µg of protein samples were electrophoresed on 
NuPAGE 10% Bis-Tris gels. The separated proteins were transferred to PVDF membrane, then incubated 
initially with primary antibody (polyclonal anti-TR1), and finally with HRP-conjugated secondary 
antibody. Membrane was reacted with ECL reagent and exposed to X-ray film. 
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Supplementary Figure 1. Analysis of 75Se-labeled selenoproteins. The gel shown in Figure 1 in the 
manuscript text was subjected to PhosphorImager analysis and the relative intensities of Thioredoxin 
reductase 1, glutathione peroxidase 1 and selenoprotein 15 bands were determined using a ImageQuant 
5.2 (Molecular Dynamics) program. It should also be noted that SPS2 and TR3, which are 
expressed in all cell types, albeit in lower levels than TR1, migrate at the similar position as TR1 
on gels, contribute to the intensity of the band shown at ~55 kDa and most certainly are 
responsible for most of the remaining low 75Se-labeling at ~55 kDa shown in Fig. 1A, lane 3, of 
the text. 
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Supplementary Figure 2. Gene products associated with malignancy. RNA extracts from LLC1 cells 
stably transfected with either pU6 control or siTR1 constructs were examined for expression profiles of 
96 candidate cancer molecules using a Mouse Cancer Pathway Finder Gene Array as described in 
Materials and Methods of the manuscript. Boxes designated H and O, which are reduced approximately 
2.5 fold in siTR1 transfected cells, correspond to hepatocyte growth factor (Hgf) mRNA and osteopontin 
(Opn1) mRNA, respectively. These factors have important roles in metastasis and tumor growth (see text 
of manuscript). Several additional boxes in the figure are identified as further discussed in the text.  
 
 
 
 
 
